ATRA Atara Biotherapeutics Inc: רווח נקי למניה ב-12 החודשים האחרונים

The development of T-cell therapies remains independent of economic cycles, as confirmed by the analyzed price action where the EPS stands at -155.70. Atara Biotherapeutics (ATRA) relies on its own high-tech immunotherapy manufacturing facility in the US. Its first-mover status in the allogeneic drug sector and European licenses enable the company to maintain high profitability, outpacing its competitors.

Atara Biotherapeutics (ATRA) is developing cell therapy, where financial success depends on biological factors and R&D funding rather than economic cycles. This indicator measures the rate of change in earnings per share over a rolling year, allowing the stability of returns to be assessed through the dynamics of the annual percentage change in EPS TTM and the asset to be timely compared with alternative defensive instruments.